We previously found that 177Lu-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2 and EGFR were more effective for RIT of s.c. MDA-MB-231/H2N human breast cancer xenografts in athymic mice than the corresponding 111In-labeled bsRICs when administered at the same amounts (11.0 MBq) (Razumienko et al., 2016). This evidence concerns the gene EGFR and breast carcinoma.